C
AVIR icon

Covestor’s Atea Pharmaceuticals AVIR Stock Holding History

Covestor’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$0 Buy
+36
New +$179 ﹤0.01% 2480
2025
Q4 		– Sell
-93
Closed – – 2260
2025
Q3 		$0 Buy
93
+8
+9% +$27 ﹤0.01% 2279
2025
Q2 		$0 Buy
85
+3
+4% +$9 ﹤0.01% 2199
2025
Q1 		$0 Buy
82
+15
+22% +$47 ﹤0.01% 2207
2024
Q4 		$0 Buy
67
+1
+2% +$3 ﹤0.01% 2223
2024
Q3 		$0 Sell
66
-52
-44% -$189 ﹤0.01% 2206
2024
Q2 		$0 Buy
+118
New +$440 ﹤0.01% 2232
2023
Q3 		– Sell
-83
Closed – – 2104
2023
Q2 		$0 Sell
83
-929
-92% -$3.48K ﹤0.01% 2121
2023
Q1 		$3K Buy
+1,012
New +$4.11K ﹤0.01% 1651
2022
Q1 		– Sell
-40
Closed – – 2093
2021
Q4 		$0 Buy
+40
New +$623 ﹤0.01% 2104

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Covestor's AVIR Position: Q2 2026 in Review

Covestor opened a new position in Atea Pharmaceuticals (AVIR) in Q2 2026: 36 shares worth $0. The stake represents ﹤0.01% of the portfolio and ranks #2480 among its holdings. This is a return to the name: Covestor previously reported a position in AVIR as recently as Q3 2025.

Covestor first reported a position in AVIR in Q4 2021 and has held it in 10 quarters since. The position peaked at $3K in Q1 2023. 124 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • Covestor held 36 shares of Atea Pharmaceuticals worth $0 as of Q2 2026.
  • Atea Pharmaceuticals was a new Covestor position in Q2 2026.
  • Atea Pharmaceuticals made up ﹤0.01% of Covestor's portfolio in Q2 2026, its #2480 holding.
  • Covestor first reported a position in Atea Pharmaceuticals in Q4 2021 and has held it in 10 quarters since.
  • Covestor's Atea Pharmaceuticals position peaked at $3K in Q1 2023.
  • 124 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on Covestor's 13F filing for Q2 2026, filed 7 Aug 2026.